Why would a patient with schizophrenia be prescribed Depakote (valproic acid) together with Latuda (lurasidone)?

Why Depakote and Latuda Together for Schizophrenia

A patient with schizophrenia would be prescribed Depakote (valproic acid) together with Latuda (lurasidone) primarily as an augmentation strategy when the antipsychotic alone has not adequately controlled symptoms—particularly agitation, aggression, or impulsivity—or when the patient has comorbid bipolar features. This combination represents an off-label use of valproate as a mood stabilizer to augment antipsychotic therapy 1.

Primary Clinical Rationale

The FDA-approved indication for Latuda includes schizophrenia treatment, and notably, it is also approved as adjunctive therapy with lithium or valproate for bipolar depression 1. While this specific FDA approval is for bipolar disorder, it establishes precedent for combining lurasidone with valproate safely. The combination in schizophrenia specifically targets:

• Residual agitation and aggression that persists despite antipsychotic monotherapy
• Impulsivity and hostility that may not fully respond to antipsychotics alone
• Schizoaffective features where mood instability overlaps with psychotic symptoms

Evidence Base

Research demonstrates that valproate augmentation can reduce excitement and hostility scores in schizophrenia patients receiving antipsychotics, without altering antipsychotic metabolism 2. A 28-day randomized trial showed faster improvement in psychopathology when divalproex was combined with atypical antipsychotics compared to monotherapy 3. However, systematic reviews reveal inconsistent overall benefits, with no clear superiority at study endpoints 4.

The evidence for this combination is mixed and not strongly supported by guidelines. Current schizophrenia treatment guidelines emphasize antipsychotic monotherapy first, with clozapine as the gold standard for treatment-resistant cases 5, 6, 7. Antipsychotic polypharmacy or augmentation with mood stabilizers should only be considered after:

1. At least two adequate trials of different antipsychotic monotherapies (4+ weeks each at therapeutic doses)
2. A trial of clozapine (if not contraindicated)
3. Confirmation of medication adherence through long-acting injectables or blood level monitoring
4. Ruling out substance use or medical causes of persistent symptoms

5, 6

When This Combination Makes Clinical Sense

Valproate augmentation is most justified when:

• The patient has prominent aggressive or agitated behaviors that pose safety risks and have not responded to antipsychotic optimization
• There are schizoaffective features with mood instability
• Clozapine has failed, is contraindicated, or refused by the patient
• The patient is already stabilized on this combination and attempting to discontinue valproate led to symptom worsening

3, 8, 9

Critical Safety Considerations

Important caveats with this combination:

• Valproate can reduce lurasidone blood levels by approximately 55% through enzyme induction, potentially requiring higher lurasidone doses 10
• Valproate carries risks of hepatotoxicity, pancreatitis, thrombocytopenia, and metabolic complications including hypoglycemia and carnitine deficiency 11, 9
• Regular monitoring is essential: liver function tests, complete blood counts, and valproate levels every 3-6 months 11
• In women of childbearing age, valproate should be avoided due to teratogenicity and polycystic ovary syndrome risk 11

Alternative Approaches to Consider

Before settling on this combination long-term, the treatment team should have explored:

1. Clozapine monotherapy (most effective for treatment-resistant schizophrenia) 6, 7
2. Switching to a different antipsychotic with better efficacy profile
3. Long-acting injectable antipsychotics to ensure adherence 7
4. Lithium augmentation as an alternative mood stabilizer (may be safer than valproate for aggression) 9

Clinical Bottom Line

This combination represents a pragmatic but not guideline-preferred approach to managing schizophrenia with prominent behavioral dyscontrol or mood symptoms. The FDA approval of lurasidone with valproate for bipolar depression 1 provides some safety reassurance, but efficacy data specifically for schizophrenia remains limited 4. If the patient is stable on this regimen, continuation may be reasonable, but periodic attempts to simplify to monotherapy should be considered 5. Document the specific target symptoms (agitation, aggression, mood instability) and monitor whether the combination provides measurable benefit over antipsychotic monotherapy alone.